We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Agilent's Acquisition of Proscia to Advance AI-Enabled Digital Pathology Workflows

By LabMedica International staff writers
Posted on 14 Oct 2026

Agilent Technologies Inc. More...

has entered into a definitive agreement to acquire Proscia, a provider of digital pathology software for clinical and life-sciences customers. The all-cash transaction is valued at USD 240 million in cash at closing, with up to an additional USD 30 million based on future performance milestones. Proscia is an independent provider of enterprise digital pathology software and a central operating layer for digital pathology.

Proscia’s Concentriq platform brings intelligence to scientists, pathologists, and laboratory leaders involved in medicine-related decision-making. The digital pathology technology connects slide scanners, laboratory information systems, image-analysis applications, AI tools, people, and data so customers can manage images, data, and workflows in one unified environment. Proscia serves more than 4,000 laboratories, hospitals, and clinics, as well as 16 of the top 20 pharmaceutical companies, and reported trailing 12-month revenue exceeding USD 18 million.

Proscia’s vendor-agnostic digital pathology platform holds U.S. Food and Drug Administration (FDA) 510(k) clearance for primary diagnosis. The transaction builds on a multi-year distribution agreement between Agilent and Proscia signed in September 2022 to offer a comprehensive digital diagnostic-pathology system. The acquisition is subject to customary closing conditions and is expected to close early in Agilent’s fiscal year 2027, after which Proscia will become part of the Agilent Life Sciences and Diagnostics Markets Group.

“Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market,” said Agilent President and CEO Padraig McDonnell. 

“The acquisition establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation in a workflow that supports biomarker research through routine clinical use. With Proscia’s leading platform and talented team, we will be better equipped to help laboratories and biopharma customers manage and derive insights from pathology data. We look forward to welcoming the Proscia team to Agilent and working together to accelerate adoption of AI-enabled pathology workflows to advance drug discovery and companion-diagnostics solutions and create long-term value for customers and shareholder,” said McDonnell.

Related Links
Agilent
Proscia


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.